Bristol Myers Squibb Announces Positive Phase 1 Results for Novel EGFRxHER3 Bispecific ADC in Metastatic NSCLC at ESMO 2025

Reuters
2025.10.13 10:59
portai
I'm PortAI, I can summarize articles.

Bristol Myers Squibb announced positive Phase 1 results for its EGFRxHER3 bispecific ADC, izalontamab brengitecan (iza-bren), in metastatic non-small cell lung cancer (NSCLC). These findings will be presented at the ESMO Congress 2025, highlighting over 50 studies across various cancer types. The results support the FDA’s Breakthrough Therapy designation for iza-bren in advanced EGFR-mutated NSCLC. The congress is scheduled for October 17-21, 2025, in Berlin, Germany.

Bristol Myers Squibb Company announced that new data from its oncology portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place October 17-21 in Berlin, Germany. The company will showcase results from more than 50 studies, including both company-sponsored and investigator-sponsored research, spanning over 10 cancer types. Among the key presentations is the first disclosure of results from a global Phase 1 study of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFRxHER3 bispecific antibody-drug conjugate, in patients with metastatic non-small cell lung cancer and other solid tumors. These results supported the FDA’s Breakthrough Therapy designation for iza-bren in advanced EGFR-mutated non-small cell lung cancer. All results are scheduled to be presented at the upcoming ESMO 2025 Congress. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20251010063007) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.